2023-508442-18-00招募中3 期
Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM). Phase 3 pragmatic multicenter open labelled randomized trial.
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla27 个研究点 分布在 1 个国家目标入组 364 人开始时间: 2024年4月10日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 364
- 试验地点
- 27
- 主要终点
- Due to clinical failure in OCD evaluation: - Non-disappearance or return to baseline of all initial clinical criteria. - Non-disappearance of symptoms and signs of infection. - Appearance of new infection symptoms. - Need to suspend antibiotic or add another due to lack of effectiveness. - In debridement is performed with retention: intraoperative and BM sonication cultures when removing BM when the fracture consolidates. - Use of the REBORNE fracture consolidation scale.
研究概览
简要总结
To evaluate whether, after performing surgical treatment (debridement with implant retention or debridement with implant removal) in patients with IOM due to a large bone fracture, a short treatment is as effective as a longer treatment.
研究设计
- 分配方式
- Randomized
- 主要目的
- Duratiom
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 18-64 Years, 0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Inclusion criteria when performing DAIR (implant retention): the CI (9) are listed below:
- •Age greater than or equal to 14 years.
- •Stabilized fracture, even non-consolidated.
- •Controlled infection (absence of signs or symptoms of sepsis).
- •Early BM infection (that occurs in the first 2 weeks after implant surgery) or delayed BM infection (that occurs between 3 and 10 weeks after implant surgery).
- •Availability of antibiotics active against the isolated microorganism.
- •Absence of bone exposure. Patients who initially had bone exposure, but during debridement surgery, bone coverage was performed by any method (skin approximation, grafting, vacuum therapy) may be included in the criteria.
- •Patients who have signed the informed consent, in the case of minors, signature of the legal guardians and assent of the minor.
- •If there is a possibility of pregnancy or parenthood, agree to the use of a highly effective method of birth control during the treatment phase of the trial.
- •Infections of osteosynthesis material implanted after an osteotomy due to corrective surgery may be included.
- •Inclusion criteria when implant removal is performed: the CI (9) are listed below:
- •Age greater than or equal to 14 years.
- •Controlled infection (absence of signs or symptoms of sepsis).
- •Early BM infection (that occurs in the first 3 weeks after implant surgery) or delayed BM infection (that occurs between 4 and 10 weeks after implant surgery).
- •Availability of antibiotics active against the isolated microorganism.
- •Absence of bone exposure. Patients who initially had bone exposure, but during the debridement and material removal surgery, bone coverage was performed by any method (skin approximation, graft, vacuum therapy), can be included in the criteria.
- •Patients who have signed the informed consent, in the case of minors, signature of the legal guardians and assent of the minor.
- •Patients may be included if DAIR was performed in the first surgery, but subsequently decided to remove the implant, as long as the rest of the inclusion criteria are met.
- •If there is a possibility of pregnancy or parenthood, agree to the use of a highly effective method of birth control during the treatment phase of the trial.
- •Infections of osteosynthesis material implanted after an osteotomy due to corrective surgery may be included.
排除标准
- •Exclusion criteria when performing DAIR (implant retention): the CE (9) are listed below:
- •Late infections (those that occur more than 10 weeks after implant surgery).
- •Infections of osteosynthesis material in non-long bones.
- •Infections of the revision osteosynthesis material or that occur after previous surgeries.
- •Patients in whom it is unlikely to complete follow-up for at least 1 year after completing antibiotic treatment.
- •Pregnant or breastfeeding women.
- •Patients in whom there may be interactions with medications or contraindications described in the technical sheets of the investigational medications used in this trial.
- •Infections due to mycobacteria, fungi and parasites.
- •Patients in whom all the material is replaced during the debridement at the same surgical time.
- •Infections of external fixators.
- •Exclusion criteria when performing DAIR with REMOVAL of the implant): the CE (10) are listed below:
- •Late infections (those that occur more than 10 weeks after implant surgery).
- •Infections of osteosynthesis material in non-long bones.
- •Infections of the revision osteosynthesis material or that occur after previous surgeries.
- •Inability to perform a good debridement, bone curettage, or resection in the presence of osteomyelitis.
- •Infections treated with removal of the implant but in which the reimplantation of a new osteosynthesis material is performed in the same surgical procedure.
- •Patients in whom it is unlikely to complete follow-up for at least 1 year after completing antibiotic treatment.
- •Pregnant or breastfeeding women.
- •Patients in whom there may be interactions with medications or contraindications described in the technical sheets of the investigational medications used in this trial.
- •Infections due to mycobacteria, fungi and parasites.
- •Infections of external fixators.
结局指标
主要结局
Due to clinical failure in OCD evaluation: - Non-disappearance or return to baseline of all initial clinical criteria. - Non-disappearance of symptoms and signs of infection. - Appearance of new infection symptoms. - Need to suspend antibiotic or add another due to lack of effectiveness. - In debridement is performed with retention: intraoperative and BM sonication cultures when removing BM when the fracture consolidates. - Use of the REBORNE fracture consolidation scale.
Due to clinical failure in OCD evaluation: - Non-disappearance or return to baseline of all initial clinical criteria. - Non-disappearance of symptoms and signs of infection. - Appearance of new infection symptoms. - Need to suspend antibiotic or add another due to lack of effectiveness. - In debridement is performed with retention: intraoperative and BM sonication cultures when removing BM when the fracture consolidates. - Use of the REBORNE fracture consolidation scale.
次要结局
- Clinical variable: -Efficacy of each group of antibiotics -Development of secondary infections -Recurrence rate (recurrences and reinfections) -Need for new surgeries (debridement, removal of material, coverage, amputation). -Evaluation of different reconstruction strategies (bone and soft tissue) carried out in order to recover lost functionality. -Functional status (defined as the recovery of the functionality of the extremity prior to the fracture) and quality of life.
- Microbiological variable: -Development of resistance during treatment. -C. difficile infection during or 30 days after treatment
- Adverse effects and complications: Occurrence of adverse events (frequency and severity), including death (ie, all-cause mortality).
- Consumption of health resources: The consumption of health resources will be evaluated for each treatment group: days of antibiotic treatment, hospital stay, readmissions, number of surgeries performed.
研究者
Unidad de Investigación Clínica y ensayos clínicos UICEC HUVR
Scientific
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
研究点 (27)
Loading locations...
相似试验
已完成
不适用
A Study Comparing Two Different Denture Base Materials in Implant Retained OverdenturesNCT07271641Al-Azhar University16
进行中（未招募）
不适用
Toluidine Blue-Based Photodynamic Therapy for Antibacterial Activity and Postoperative PainNCT07266233Ataturk University50
招募中
3 期
A2B-trial Antibioprophylaxis for excision-graft surgery in burn patient : a multicenter randomized double-bling study2024-514349-13-00Assistance Publique Hopitaux De Paris506
Enrolling By Invitation
不适用
Implant-Related Infections in Patients With Skeletal SarcomasNCT07264296Vastra Gotaland Region40
尚未招募
不适用
Herbal intracanal medicaments in dentistryCTRI/2022/09/045532Dr Kunal Bedi40